a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
Expert Rev Clin Immunol. 2018 Feb;14(2):155-161. doi: 10.1080/1744666X.2018.1427065. Epub 2018 Jan 16.
Psoriasis has a profound impact on patients' lives, but adherence to topical treatment of psoriasis is still poor. Biologic treatment has revolutionized the management of psoriasis, but adherence to treatment may still be a barrier for some patients. Areas covered: A PubMed search was conducted in August 2017 using the terms 'biologics psoriasis adherence' and 'biologics psoriasis survival.' Additional articles were obtained by perusing the references of articles identified in the original PubMed search. Articles that did not specifically mention 'survival,' 'adherence,' or 'persistence' were not included. We review the measures used to assess adherence to biologics for psoriasis and the factors impacting drug survival and adherence rates for biologics in psoriasis. Expert commentary: Drug survival and adherence rates for biologic therapy is less than ideal but may be modifiable. Means that may improve adherence and drug survival include individualized choice of biologic and providing additional support for patients who are at increased risk for prematurely stopping treatment.
银屑病对患者的生活有深远影响，但患者对银屑病的局部治疗的依从性仍然较差。生物制剂治疗已经彻底改变了银屑病的治疗方式，但治疗的依从性对某些患者来说可能仍然是一个障碍。
2017 年 8 月，使用术语“生物制剂银屑病的依从性”和“生物制剂银屑病的生存”，在 PubMed 上进行了一次检索。通过查阅原始 PubMed 检索中确定的文章的参考文献，获得了其他文章。未特别提及“生存”、“依从性”或“持久性”的文章不包括在内。我们回顾了用于评估银屑病生物制剂依从性的措施，以及影响生物制剂药物生存和银屑病患者依从性的因素。
生物制剂治疗的药物生存和依从率不尽人意，但可能是可以改变的。可能提高依从性和药物生存的方法包括个体化选择生物制剂，并为有提前停止治疗风险的患者提供额外的支持。
